By binding to its consensus sequence in the TET1 promoter, p65 suppresses TET1 expression in breast cancer cells upon NF-κB activation; similar results have been reported in thyroid cancer, lung cancer, and melanoma.194 TET2 mutations are linked to myeloid malignancies, and research by Ko et al. demonstrated that these mutations reduce the enzyme’s catalytic activity. This evidence concerns the gene TET1 and thyroid gland carcinoma.